Feb 04, 2021
Precigen to Participate in Guggenheim Healthcare Talks Oncology Day
Jan 22, 2021
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
Jan 13, 2021
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
Jan 06, 2021
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 08, 2020
Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments
Nov 16, 2020
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator(TM) System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials
Nov 02, 2020
Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December
Oct 20, 2020
Precigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head of Business Development
Oct 15, 2020
Precigen's UltraPorator(TM) Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials
Aug 06, 2020
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
Jun 11, 2020
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum
Jun 04, 2020
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders
May 06, 2020
Precigen Reports First Quarter 2020 Financial Results
Apr 29, 2020
Precigen to Announce First Quarter 2020 Financial Results on May 6th
Apr 20, 2020
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse(TM) Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Feb 24, 2020
Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd
Feb 03, 2020
Precigen Completes Series Of Transactions To Solidify Healthcare Focus
Jan 06, 2020
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T(TM) in Patients with Acute Myeloid Leukemia (AML)
Nov 04, 2019
Intrexon to Announce Third Quarter Financial Results on November 12th
Aug 05, 2019
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T(TM) in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer